PMC:2948432 / 26552-27157 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/2948432","sourcedb":"PMC","sourceid":"2948432","source_url":"https://www.ncbi.nlm.nih.gov/pmc/2948432","text":"There was no significant association between BRAF and NRAS mutation status and reduced gene dosage in the CDKN2A/CDKN2B regions with the Wilcoxon Two-Sample test, but there was a trend toward an association between the presence of BRAF mutations and loss at regions coding for CDKN2A (one sided P = 0.06, two sided P = 0.12). The absence of BRAF mutation was associated with reduced gene dosage at MTAP (one sided P = 0.04, two sided P = 0.09) and the absence of an NRAS mutation was (borderline) associated with reduced gene dosage at the interferon gene cluster (one sided P = 0.05, two sided P = 0.10).","tracks":[]}